<DOC>
	<DOCNO>NCT00342043</DOCNO>
	<brief_summary>This study , sponsor National Institutes Health University Bamako Mali , Africa , examine factor may protect progression malaria mild severe disease . Infection malaria parasite cause disease range severity mild symptom severe . A good understanding factor protect disease progression may help scientist develop improve method disease prevention treatment . The objective study : - Identify difference protective factor severe malaria Malinke child reside two Mali village , Kela Kangaba . Genetic variation hemoglobin protein call HbS HbC appear confer protection severe disease child others . HbC appear protect young Malinke child live Kela , nearby Kangaba , HbS protect child Kangaba Kela . In addition , deficiency enzyme produce red blood cell call G6PD protects male , female , severe malaria . - Investigate fetal hemoglobin ( HbF ) may protect malaria infant determine HbS , HbC , G6PD deficiency , beta-thalassemia trait affect rate HbF decline first 2 year life . Children 11 year age seek medical care Kangaba Kela health center symptoms malaria may eligible study . Each screen medical history , physical examination blood test . In addition , healthy infant born woman refer field site clinic may enrol newborn study . Participants undergo follow procedure : Children mild malaria treat artesunate amodiaquine . Those severe malaria treat quinine . Blood collect finger prick every day 4 day evaluate response treatment genetic testing . Some blood store future research relate malaria . Newborns heel finger prick 1 , 3 6 month collect small blood sample genetic testing . In addition , time birth , small amount blood collect one blood vessel placenta . Some infant may follow 2 year , additional drop blood take 12 , 18 24 month . Some blood store future research relate malaria .</brief_summary>
	<brief_title>Examination Protective Factors Against Severe Malaria</brief_title>
	<detailed_description>Our previous case-control study ( protocol # 01-I-N020 ) establish hemoglobin ( Hb ) C protect severe malaria Dogon ethnic group Mali , West Africa . We believe abnormal display major parasite virulence antigen ( PfEMP-1 ) surface HbC erythrocytes account protection . Whether mechanism mediates protection mutant erythrocytes remain investigated . The principal objective current protocol investigate whether HbC also protect severe malaria Malinke Kela , historically give rise Dogon . Our preliminary data protocol # 02-I-N285 suggest HbC HbS ( sickle trait ) protect young Malinke child Kela , opposite true Malinke child Kangaba , nearby village . To confirm novel preliminary finding investigate candidate mechanism protection , ongoing case-control study require additional 150 severe malaria patient less 5 year old , Malinke ethnicity , reside either Kangaba Kela village , normal G6PD activity . Children le 11 year old diagnose either severe ( case ) uncomplicated ( control ) malaria test hemoglobinopathy G6PD deficiency . Severe uncomplicated malaria patient treat parenteral quinine oral artemisinin combination therapy , respectively , standard care Mali . Principal outcome measure include comparison frequency HbC , HbS , G6PD deficiency case control ; odds ratios 95 % confidence interval determine degree statistical significance severe malaria protection .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . All malaria patient enrol casecontrol study le 11 year old . 2 . Uncomplicated malaria : Axillary temperature great 37.5 degree Celsius history fever , sign symptom malaria ( e.g . headache , body ache , malaise ) , asexual parasite density le 500,000 per microliter blood , criterion severe malaria ( see next paragraph ) , etiology febrile illness ( e.g . respiratory tract infection , cellulitis ) clinical examination . 3 . Severe malaria : Asexual parasite density great equal 100,000/uL parasitemia density plus one following : coma ( define Blantyre coma score less equal 2 ) , convulsion ( witnessed investigator ) , severe prostration , severe anemia ( hemoglobin le 5 g/dL ) , respiratory distress , hypoglycemia ( serum glucose less 40 mg/dL ) , jaundice/icterus , shock ( systolic blood pressure le 50 mmHg , rapid pulse , cool extremity ) , cessation eat drinking , repetitive vomiting . EXCLUSION CRITERIA : Patients parasitemic yet find clinical examination another etiology febrile illness ( e.g. , respiratory tract infection , cellulitis ) formally enrol protocol , may treat malaria coexist infection study team .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>April 16, 2009</verification_date>
	<keyword>Sickle Trait</keyword>
	<keyword>Fetal Hemoglobin</keyword>
	<keyword>Hemoglobin C</keyword>
	<keyword>Beta-Thalassemia</keyword>
	<keyword>Artesunate-Amodiaquine</keyword>
</DOC>